Growth in the European autoimmune diseases therapeutics market is being spurred by ongoing awareness campaigns, the acceptance of biologics by doctors and an expanding patient base.With over 70 autoimmune diseases including rheumatoid arthritis and multiple sclerosis (MS), there exists tremendous scope in translating current knowledge to producing innovative, efficient and economical therapeutics.